Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evonik Industries AG    EVK   DE000EVNK013

EVONIK INDUSTRIES AG

(EVK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Evonik Industries : confirms full-year earnings outlook despite ongoing weakness in global economy

share with twitter share with LinkedIn share with facebook
11/05/2019 | 01:10am EDT
communications
Eve Wang
zhe.wang@evonik.com
Press release
Group
November 5, 2019
Evonik confirms full-year earnings outlook despite ongoing weakness in global economy
  • 2019: Adjusted EBITDA to remain at least stable
  • Free cash flow outlook for full year confirmed and specified: around €700 million
  • Q3: Sales and operating earnings below year-ago period
  • Stricter cost discipline supports earnings

Evonik is sticking to its full-year earnings outlook despite an ongoing weakness in the global economy.

The company expects adjusted EBITDA to remain at least stable compared with last year. Sales are now expected to be slightly lower than the previous year because of lower demand. Evonik had expected sales to remain stable. In 2018 Evonik generated - excluding the divested Methacrylates business - sales of

€13.3 billion and adjusted EBITDA of €2.15 billion.

'We prepared ourselves at an early stage with stricter cost discipline and additional contingency measures for a cooling global economy,' said Christian Kullmann, chairman of Evonik's executive board. 'We are being very proactive to ensure we meet our full-year outlook.'

The 2018 initiated efficiency program to reduce administrative and selling expenses by €200 million annually has been accelerated. By end of this year, Evonik will achieve €120 million of savings, €20 million more than originally planned. A further €20 million will be saved with additional contingency measures such as delaying new hires and more restrictive expenditure on external services.

Evonik is specifying its full-year outlook for free cash flow and

is now expecting a level of around €700 million, a significantly higher free cash flow compared with last year. This is mainly due to lower capex spending, less build-up of net working capital and the partial reimbursement of pension payments from the Contractual Trust Arrangement (CTA). The more precise outlook does not include taxes incurred from the carve out of the divested Methacrylates business.

The global economic slowdown continued to impact Evonik's performance in the third quarter. In the months July to September sales fell 3 percent to €3.23 billion due to lower volumes and selling prices. Adjusted EBITDA fell 6 percent year-on-year to €543 million.

Segment Performance

Resource Efficiency: Segment sales declined 1 percent to

€1.4 billion in the third quarter. Coatings as well as the adhesive and resins business was affected by the global economic slowdown, especially in the automotive and coatings sector.

Sales volumes declined for industry-related silica applications.

In contrast, high-performance polymers benefited from solid demand for membranes and from the 3D printing industry. Crosslinkers saw high demand from the wind industry.

Adjusted EBITDA dropped 4 percent to €322 million.

Nutrition & Care: Sales declined 2 percent to €1.14 billion in the third quarter. Demand for essential amino acids for animal nutrition remained high while selling prices declined further. In the Health Care business sales increased, especially due to good demand for pharma and food ingredients. Sales increased significantly for polyurethane-foam additives, mostly on high demand for durable consumer goods and insulation. Adjusted EBITDA at the segment dropped 11 percent to €188 million.

Performance Materials: Sales in the third quarter decreased

20 percent to €475 million compared with the prior-year quarter. Development at Performance Intermediates was impaired by a lower oil and naphtha price and slightly lower selling prices. Continuing constraints in raw-material supply and technical problems at the C4 plants in Marl and Antwerp weighed on earnings. At Functional Solutions the alkoxides business developed well. Adjusted EBITDA declined 25 percent to

€47 million at the segment.

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

Evonik's international activities are organized into six regions. The Asia Pacific North region is headquartered in Shanghai. Sales in Asia Pacific North reached €1.97 billion in 2018. Evonik regards China as one of the driving forces of the global economy and we consequently endeavor to grow our business here. The company now employs over 2,500 employees and has in total of 10 production sites in China.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Disclaimer

Evonik Industries AG published this content on 05 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 November 2019 06:09:09 UTC

share with twitter share with LinkedIn share with facebook
All news about EVONIK INDUSTRIES AG
09/15EVONIK INDUSTRIES : Virtual Commerzbank Corporate Conference, Frankfurt
PU
09/14EVONIK INDUSTRIES : launches its own GAA-product GuanAMINO®
PU
09/11EVONIK : Credit Suisse lowers its rating to Sell
MD
09/08German chemicals group sees 2020 output falling 3% and revenues down 6%
RE
09/03EVONIK INDUSTRIES : Unilever accredits its collaboration with Evonik as one key ..
PU
09/03EVONIK : Buy rating from Warburg Research
MD
09/03EVONIK : Buy rating from Goldman Sachs
MD
09/02EVONIK : JP Morgan reiterates its Buy rating
MD
09/02Unilever to drop fossil fuels from cleaning products by 2030
RE
09/01EVONIK : UBS reaffirms its Sell rating
MD
More news
Financials
Sales 2020 12 251 M 14 507 M 14 507 M
Net income 2020 564 M 668 M 668 M
Net Debt 2020 3 238 M 3 835 M 3 835 M
P/E ratio 2020 19,6x
Yield 2020 4,97%
Capitalization 10 754 M 12 759 M 12 735 M
EV / Sales 2020 1,14x
EV / Sales 2021 1,09x
Nbr of Employees 32 621
Free-Float 41,1%
Chart EVONIK INDUSTRIES AG
Duration : Period :
Evonik Industries AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVONIK INDUSTRIES AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 26,86 €
Last Close Price 23,12 €
Spread / Highest target 42,7%
Spread / Average Target 16,2%
Spread / Lowest Target -4,84%
EPS Revisions
Managers
NameTitle
Christian Kullmann Chairman-Executive Board
Bernd Tönjes Chairman-Supervisory Board
Ute Wolf Chief Financial Officer
Andreas Fischer Chief Innovation Officer
Siegfried Luther Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
EVONIK INDUSTRIES AG-15.03%12 759
BASF SE-19.54%59 049
SHIN-ETSU CHEMICAL CO., LTD.16.83%56 096
DUPONT DE NEMOURS, INC.-7.65%43 509
ROYAL DSM N.V.19.04%27 803
FMC CORPORATION13.05%14 325